- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05486195
A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect
August 2, 2022 updated by: AbbVie
A First-in-Human, Randomized, Placebo-controlled, Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including Receptor Occupancy Measurements After Single Dose of SDI-118 and an Assessment of Food Effect
This is a First-in-Human, Randomized, Placebo-controlled, Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects including Receptor Occupancy Measurements after Single Dose of SDI-118 and an Assessment of Food Effect.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leuven, Belgium, B-3000
- Centre for Clinical Pharmacology, UZ Leuven
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy male subjects, 18 to 50 years of age, inclusive.
- Non-smokers or abstinence from tobacco for at least 3 months prior to screening.
- Body mass index (BMI) between 18 and 30 kg/m2, inclusive, with a minimum weight of 50 kg and maximum of 100 kg.
- Venous access sufficient to allow blood sampling as per the protocol.
- Agree to abstain from alcohol intake 24h before each administration of study drug, during the in-patient period of the study and 24 hours prior to all other out-patient clinic visits.
- Have given written informed consent approved by the relevant Ethics Committee (EC) governing the site.
- In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the clinical study protocol restrictions and requirements.
- Subjects and their partners of childbearing potential must be willing to use 2 methods of contraception, one of which must be a barrier method, for the duration of the study and up to 90 days after the last dose.
Specifically, Part B/PET related inclusion criteria:
- Adequate arterial circulation in both hands (Allen's test).
- MRI scan without clinically significant abnormalities.
Specifically, Part C/FE related inclusion criteria:
- Subjects are not vegetarian and willing to eat a standardized high fat breakfast including butter and bacon.
Exclusion Criteria:
- History or symptoms of any significant disease including (but not limited to), neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal (GI), hepatic, or renal disorder.
- Positive Hepatitis B surface antigen (HBs Ag), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
- Use of any medications (prescription or over-the-counter (OTC)), vitamin, mineral, herbal, and dietary supplements (including grapefruit products) within 7 days of study drug administration, or less than 5 half-lives (whichever is longer).
- Have an estimated Glomerular Filtration Rate (eGFR) <80 mL/min/1.73m2.
Any of the following findings in the resting ECG:
- QTcF> 450 or < 300 msec at screening or baseline visit,
- Notable resting bradycardia (HR < 40 bpm) or tachycardia (HR > 100 bpm) at screening or baseline visit,
- Personal or family history of congenital long QT syndrome or sudden death,
- Screening or baseline ECG with QRS and/or T wave judged to be unfavourable for a consistently accurate QT measurement (e.g. neuromuscular artefact that cannot be readily eliminated, arrhythmias, indistinct QRS onset, low amplitude T wave, merged T- and U-waves, prominent U waves),
- Evidence of atrial fibrillation, atrial flutter, Left Bundle Branch Block (LBBB), Wolf-Parkinson-White Syndrome, or cardiac pacemaker at screening or baseline visit (note: a first degree heart block with PR not exceeding 250 msec can be allowed).
Specifically, Part B/PET related exclusion criteria:
- Previous inclusion in a research study and/or medical protocol involving nuclear medicine, PET or radiological investigations with significant radiation burden (a significant radiation burden being defined as International Commission on Radiological Protection (ICRP) category IIb or above: no more than 1 mSv in addition to the natural background radiation in the previous 12 months including the dose from the study).
- Subject who fulfils any of the MRI contraindications on the standard radiography screening questionnaire (including the presence of ferromagnetic metal in the body or heart pacemaker).
- History of or suffers from claustrophobia or feels that they will be unable to lie still on their back in the PET camera for a period of 2 hours.
- Any known allergy to local anaesthetics or heparin.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SDI-118 Dose 1
|
SDI-118 Powder in Capsule
|
Experimental: SDI-118 Dose 2
|
SDI-118 Powder in Capsule
|
Experimental: SDI-118 Dose 3
|
SDI-118 Powder in Capsule
|
Experimental: SDI-118 Dose 4
|
SDI-118 Powder in Capsule
|
Experimental: SDI-118 Dose 5
|
SDI-118 Powder in Capsule
|
Experimental: SDI-118 Dose 6
|
SDI-118 Powder in Capsule
|
Placebo Comparator: SDI-118 Placebo
|
Matching Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with Adverse Events (AEs)
Time Frame: 21 Days
|
Adverse events (AEs) will be coded using medical dictionary for regulatory activities (MedDRA).
An AE is any untoward medical occurrence in a participant administered a study drug and which does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical product whether or not considered related to the medical product.
An AE is considered "serious" if, in the view of either the investigator or sponsor, the event: results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires hospitalization or prolongation to hospitalization, or other medically important event.
|
21 Days
|
Number of participants with laboratory value abnormalities and/or adverse events (AEs)
Time Frame: 21 Days
|
Number of participants with potentially clinically significant laboratory values (hematology/chemistry/urinalysis)
|
21 Days
|
Number of participants with vital sign abnormalities and/or adverse events (AEs)
Time Frame: 21 Days
|
Number of participants with potentially clinically significant vital sign values
|
21 Days
|
Number of participants with temperature abnormalities and/or adverse events (AEs)
Time Frame: 21 Days
|
Number of participants with potentially clinically significant temperature values
|
21 Days
|
Number of participants with routine 12 lead electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)
Time Frame: 21 Days
|
Number of participants with potentially clinically significant ECG values.
|
21 Days
|
Number of participants with routine physical examination abnormalities and/or Adverse Events (AEs)
Time Frame: 21 Days
|
Number of participants with potentially clinically significant changes in physical examination.
|
21 Days
|
Number of participants with routine neurological examination abnormalities and/or Adverse Events (AEs)
Time Frame: 21 Days
|
Number of participants with potentially clinically significant changes in neurological examination.
|
21 Days
|
Number of participants with abnormalities on Profile of Mood States (Brief) and/or Adverse Events (AEs)
Time Frame: 21 Days
|
Number of participants with potentially clinically significant changes in Profile of Mood States (Brief) values.
|
21 Days
|
Number of participants with abnormalities on Bond-Lader-VAS and/or Adverse Events (AEs)
Time Frame: 21 Days
|
Number of participants with potentially clinically significant changes in Bond-Lader VAS values.
|
21 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jan deHoon, MD, UZ Leuven
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 14, 2019
Primary Completion (Actual)
July 29, 2019
Study Completion (Actual)
March 11, 2020
Study Registration Dates
First Submitted
August 2, 2022
First Submitted That Met QC Criteria
August 2, 2022
First Posted (Actual)
August 3, 2022
Study Record Updates
Last Update Posted (Actual)
August 3, 2022
Last Update Submitted That Met QC Criteria
August 2, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SYND001
- 2018-004022-28 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Disorders
-
University of California, San FranciscoNational Institute on Aging (NIA)Active, not recruitingMild Cognitive Impairment | Cognitive Decline | Cognitive Deterioration | Cognitive Impairment, Mild | Cognitive Deficits, MildUnited States
-
FH Joanneum Gesellschaft mbHAustrian Research Promotion AgencyRecruiting
-
MoCA Clinic and InstituteActive, not recruitingCognitive Impairment | Cognitive Change | Cognitive Deficit | Assessment, SelfCanada
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Psychology Software Tools, Inc.National Institute on Aging (NIA)CompletedCognitive Impairment | Cognitive Dysfunction | Cognitive Change | Cognitive DeclineUnited States
-
The Cleveland ClinicTerminatedMild Cognitive Impairment | Mild Cognitive DisorderUnited States
-
National Taiwan University HospitalNational Taiwan Science Education Center(NTSEC)RecruitingCognitive Training | Subjective Cognitive DeclineTaiwan
-
Zhejiang UniversityRecruitingMild Cognitive Impairment | Cognitive Function | Cognitive DeclineChina
-
Azienda Ospedaliero-Universitaria di ParmaActive, not recruitingCognitive Deficit | DysglycemiaItaly
-
University of California, San FranciscoNational Institute on Aging (NIA)CompletedCognitive Impairment | Aging | Mild Cognitive Impairment | Cognitive Training | Cognitive Aging | Cognitively Normal Older AdultsUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States